The FDA’s Oncologic Drugs Advisory Committee narrowly voted against the approval of Zusduri, citing the lack of a completely ...

Martin Kulldorff and Robert Malone, both outspoken vaccine skeptics, have received compensation for their expert ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

Scientists and analysts express concern that the newly appointed members—which include known anti-vaxxers—could relitigate ...

The rehired staff, who number around 460, work with the CDC’s viral disease prevention efforts and sexual health testing labs ...

The biopharma job market failed to turn around in May, but employers were still hiring, especially in Indiana and California, ...

FDA Commissioner Marty Makary and CBER Director Vinay Prasad published an article in JAMA on Tuesday outlining the FDA’s ...

Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

After enduring multiple rounds of layoffs last year, Genentech’s employees are facing more uncertainty as the Roche unit lets ...

Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...